What is Rapid Pathogen Screening?
Rapid Pathogen Screening is a specialized developer and manufacturer focused on the point-of-care diagnostics market. The company is best known for its innovative FebriDx test, a disposable, in-office diagnostic tool that utilizes a finger-stick blood sample to differentiate between bacterial and viral causes of acute respiratory infections. By delivering results in just 15 minutes with a 97% negative predictive value, the company provides clinicians with the necessary data to make informed triage decisions, thereby reducing the prevalence of unnecessary antibiotic prescriptions. This focus on antibiotic stewardship and clinical efficiency positions the company as a vital player in the modern medical technology ecosystem, bridging the gap between complex laboratory testing and immediate patient care.
How much funding has Rapid Pathogen Screening raised?
Rapid Pathogen Screening has raised a total of $34.6M across 3 funding rounds:
Unspecified
$6.3M
Debt
$28M
Debt
$350K
Unspecified (2013): $6.3M with participation from Mallitz Investment Group
Debt (2014): $28M led by OrbiMed Advisors, LLC
Debt (2020): $350K supported by PPP
Key Investors in Rapid Pathogen Screening
Mallitz Investment Group
A family office platform that implements institutional discipline in debt-oriented strategies, focusing on risk-mitigated structures and proprietary private transactions.
OrbiMed Advisors, LLC
A specialized healthcare investment firm managing capital across biopharmaceuticals, medical devices, and diagnostics, known for its deep expertise in life sciences innovation cycles.
PPP
Public-Private Partnership
What's next for Rapid Pathogen Screening?
With the support of its recent strategic investment, Rapid Pathogen Screening is poised to enter a new phase of growth characterized by expanded market penetration and product portfolio diversification. The company's strategic roadmap likely involves scaling the manufacturing and distribution of the FebriDx platform to meet the rising demand for rapid diagnostic tools in primary care settings. Furthermore, the firm is expected to leverage its current capital position to invest in clinical validation studies and regulatory approvals for additional diagnostic applications. By maintaining its focus on cost-effective, high-accuracy testing, the company is well-positioned to capitalize on the increasing global emphasis on infectious disease management and the reduction of healthcare-associated costs through improved diagnostic precision.
See full Rapid Pathogen Screening company page
